Overview

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma

Status:
Active, not recruiting

Trial end date:
2036-06-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in combination with rituximab, as measured by assessment of response rates in adult participants with relapsed/refractory large B-cell lymphoma.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Cyclophosphamide
Fludarabine
Fludarabine phosphate
Lenalidomide
Rituximab